• Consensus Rating: Buy
  • Consensus Price Target: $242.40
  • Forecasted Upside: 19.27%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$203.23
▼ -2.87 (-1.39%)

This chart shows the closing price for STE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New STERIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STE

Analyst Price Target is $242.40
▲ +19.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for STERIS in the last 3 months. The average price target is $242.40, with a high forecast of $275.00 and a low forecast of $210.00. The average price target represents a 19.27% upside from the last price of $203.23.

This chart shows the closing price for STE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in STERIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/31/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/11/2022KeyCorpLower TargetOverweight$240.00 ➝ $210.00Low
9/23/2022Needham & Company LLCDowngradeBuy ➝ HoldLow
8/4/2022JMP SecuritiesLower Target$270.00 ➝ $250.00Low
8/4/2022KeyCorpLower TargetOverweight$256.00 ➝ $240.00Low
8/4/2022Needham & Company LLCLower TargetBuy$248.00 ➝ $237.00Low
7/14/2022Piper SandlerInitiated CoverageOverweight$240.00Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$275.00Medium
2/14/2022JMP SecuritiesBoost TargetMarket Outperform$250.00 ➝ $270.00Medium
2/10/2022Needham & Company LLCBoost TargetBuy$254.00 ➝ $263.00High
11/4/2021StephensBoost TargetOverweight$255.00 ➝ $270.00Medium
11/4/2021KeyCorpBoost TargetPositive ➝ Overweight$239.00 ➝ $256.00Medium
8/11/2021KeyCorpBoost TargetPositive ➝ Overweight$227.00 ➝ $239.00Medium
8/11/2021StephensBoost TargetOverweight$217.00 ➝ $255.00Medium
8/11/2021Robert W. BairdBoost TargetOutperform$230.00 ➝ $250.00Medium
5/26/2021Needham & Company LLCUpgradeHold ➝ Buy$233.00High
5/17/2021JMP SecuritiesBoost TargetMarket Outperform$217.00 ➝ $235.00N/A
5/11/2021JMP SecuritiesBoost TargetOutperform$217.00 ➝ $235.00Medium
3/11/2021KeyCorpBoost TargetOverweight$224.00 ➝ $227.00Low
2/4/2021KeyCorpUpgradeSector Weight ➝ Overweight$224.00Low
1/20/2021Raymond JamesReiterated RatingHoldLow
1/13/2021Robert W. BairdBoost TargetOutperform$200.00 ➝ $230.00Low
11/20/2020Needham & Company LLCReiterated RatingHoldMedium
10/8/2020JMP SecuritiesBoost Target$180.00 ➝ $200.00Low
10/7/2020StephensBoost Target$170.00 ➝ $200.00Low
10/7/2020Robert W. BairdBoost TargetOutperform$175.00 ➝ $200.00Medium
10/6/2020Needham & Company LLCReiterated RatingHoldMedium
9/1/2020Robert W. BairdInitiated CoverageOutperform$175.00High
8/3/2020Needham & Company LLCInitiated CoverageHoldHigh
6/9/2020Needham & Company LLCInitiated CoverageHoldMedium
5/15/2020StephensBoost TargetOverweight$145.00 ➝ $170.00Low
3/23/2020StephensLower TargetOverweight$177.00 ➝ $145.00High
2/12/2020Northcoast ResearchReiterated RatingBuyLow
2/12/2020StephensBoost TargetOverweight$165.00 ➝ $177.00High
5/22/2019JMP SecuritiesBoost TargetMarket Outperform$135.00 ➝ $150.00Low
5/15/2019StephensBoost TargetOverweight$135.00 ➝ $150.00Low
5/15/2019KeyCorpBoost TargetOverweight$135.00 ➝ $138.00Low
2/14/2019StephensReiterated RatingBuy$135.00Low
2/14/2019JMP SecuritiesReiterated RatingBuy$135.00Low
12/6/2018SidotiBoost TargetBuy ➝ Buy$155.00 ➝ $157.00Low
11/13/2018KeyCorpBoost TargetOverweight ➝ Overweight$120.00 ➝ $132.00Low
8/9/2018JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$113.00 ➝ $125.00Low
8/9/2018KeyCorpBoost TargetOverweight ➝ Overweight$115.00 ➝ $120.00Low
8/9/2018StephensReiterated RatingBuy$125.00Low
2/8/2018KeyCorpReiterated RatingBuy$103.00Medium
2/8/2018Northcoast ResearchSet TargetBuy$102.00Medium
(Data available from 1/31/2018 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
7/5/2022
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 2 very positive mentions
  • 46 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/3/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/2/2022
  • 1 very positive mentions
  • 27 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/1/2023
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/31/2023

Current Sentiment

  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
STERIS logo
STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. The Life Sciences segment designs, manufactures, and sells consumable products, equipment maintenance, specialty services, and capital equipment. The Applied Sterilization Technologies segment is involved in contract sterilization and testing services for medical device and pharmaceutical manufacturers. The Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. The company was founded in 1985 and is headquartered in Mentor, OH.
Read More

Today's Range

Now: $203.23
Low: $203.07
High: $205.85

50 Day Range

MA: $190.68
Low: $177.82
High: $206.85

52 Week Range

Now: $203.23
Low: $159.21
High: $255.93

Volume

508,083 shs

Average Volume

423,515 shs

Market Capitalization

$20.29 billion

P/E Ratio

N/A

Dividend Yield

0.91%

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of STERIS?

The following equities research analysts have issued reports on STERIS in the last year: JMP Securities, KeyCorp, Needham & Company LLC, Piper Sandler, StockNews.com, TheStreet, and Wolfe Research.
View the latest analyst ratings for STE.

What is the current price target for STERIS?

5 Wall Street analysts have set twelve-month price targets for STERIS in the last year. Their average twelve-month price target is $242.40, suggesting a possible upside of 19.3%. Wolfe Research has the highest price target set, predicting STE will reach $275.00 in the next twelve months. KeyCorp has the lowest price target set, forecasting a price of $210.00 for STERIS in the next year.
View the latest price targets for STE.

What is the current consensus analyst rating for STERIS?

STERIS currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STE will outperform the market and that investors should add to their positions of STERIS.
View the latest ratings for STE.

What other companies compete with STERIS?

How do I contact STERIS's investor relations team?

STERIS's physical mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider's listed phone number is (440) 354-2600 and its investor relations email address is [email protected] The official website for STERIS is www.steris.com. Learn More about contacing STERIS investor relations.